Clinical Pharmacology and Cardiovascular Safety of Naproxen

@article{Angiolillo2016ClinicalPA,
  title={Clinical Pharmacology and Cardiovascular Safety of Naproxen},
  author={Dominick Joseph Angiolillo and Steven M. Weisman},
  journal={American Journal of Cardiovascular Drugs},
  year={2016},
  volume={17},
  pages={97 - 107}
}
The voluntary withdrawal of Vioxx (rofecoxib) from the market in 2004, as well as the 2005 and 2014 US FDA Advisory Committee meetings about non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk, have raised questions surrounding the use of NSAIDs in at-risk populations. This paper discusses the cardiovascular safety profile of naproxen in the context of the NSAID class. The balance of evidence suggests that cardiovascular risk correlates with cyclooxygenase (COX)-2 selectivity… 
Cardiorenal Safety of OTC Analgesics
TLDR
Available data suggest that there is little cardiovascular risk when over-the-counter formulations of these agents are used as directed in their labels, and this review discusses the cardiorenal safety of the most commonly used over- the-counter analgesics, ibuprofen, naproxen, and acetaminophen.
Cardiovascular Safety of Naproxen for Treating Cancer and Noncancer Chronic Pain
  • A. Nair
  • Medicine
    Indian journal of palliative care
  • 2019
TLDR
Of all NSAIDs currently in use, naproxen seems to have a safe CVS profile and should be used with caution due to cardiovascular (CVS) side effects associated with its use.
Are NSAIDs Safe? Assessing the Risk-Benefit Profile of Nonsteroidal Anti-inflammatory Drug Use in Postoperative Pain Management
TLDR
It is found that the risks of short-term NSAID use may be overemphasized and the likelihood of renal dysfunction, bleeding, nonunion of bone, gastric complications, and finally, cardiac dysfunction do not appear to be significantly increased when NSAIDs are used appropriately after surgery.
Over-the-Counter Medicines and Diabetes Care.
TLDR
The focus of this brief review is the impact common OTC medicines might have on this group of patients, with herbal/natural agents, nonsteroidal anti-inflammatory drugs and cough/cold products selected as most deserving of attention.
Efficacy and Safety of Naproxen vs Opioids for the Treatment of Musculoskeletal Pain
SPONSORSHIP This activity is sponsored by PCEC and supported by funding from Bayer. and prescription analgesics. Prescription opioids are commonly used to treat musculoskeletal pain, although there
Anticancer and Antimicrobial Activities of Naproxen and Naproxen Derivatives.
TLDR
The effects of naproxen and containing the Naproxen moiety in important biological activities are explained and significant interest in the possibility that COX-2 inhibitors might retard or prevent the development of various cancer types, which is often characterized by COX2 expression.
Naproxen in Pain and Inflammation – A Review
TLDR
It has been established that the duration of pain relief after a single dose of naproxen is significantly greater than after the intake of ibuprofen-containing products of equal concentration in the post-operative period of dental intervention.
Novel Applications of NSAIDs: Insight and Future Perspectives in Cardiovascular, Neurodegenerative, Diabetes and Cancer Disease Therapy
TLDR
The novel mechanism of action of NSAIDs and its potential use in the pharmacotherapy of neurodegenerative, cardiovascular, diabetes and cancer diseases is discussed.
EVALUATION OF PROHYPERTENSIVE EFFECT OF MELOXICAM ON THE BLOOD PRESSURE INDICATORS
The goalis to evaluate the influence of meloxicam on the level of blood pressure among patients suffering from hypertension, as well as among patients without diseases of the cardiovascular system,
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout
TLDR
Clinical guidelines and implementation of cardiovascular risk management in daily clinical practice, as well as unmet needs and areas for further investigation, will be discussed.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 119 REFERENCES
Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association.
TLDR
There was a significant increase in the rate ratio for myocardial infarction with COX-2 inhibitors compared with placebo, and regulatory authorities in several regions of the world have introduced warning statements and advisories to both healthcare professionals and the lay public about the use of various NSAIDs.
Cardiovascular risks associated with low-dose ibuprofen and diclofenac as used OTC
TLDR
The article focuses on the risk associated with low-dose ibuprofen and diclofenac, two drugs available OTC in many countries and found a clear dose-dependent risk with both drugs and no clearly increased cardiovascular risk for doses at or below the maximal approved OTC doses.
Selectivity of NSAIDs for COX-2 and cardiovascular outcome.
TLDR
Although increased COX-2 selectivity may reduce gastrotoxicity, this may be at the cost of increasing cardiovascular risk.
Use of Non-Aspirin Nonsteroidal Antiinflammatory Drugs and the Risk of Cardiovascular Events
TLDR
Considering the large number of patients consuming NANSAIDs and the potential public health impact, the FDA's recommendation that a cardiovascular risk warning statement be included in all nonselective NanSAIDs product package inserts is justified.
Renal effects of nonselective NSAIDs and coxibs.
  • M. Weir
  • Medicine
    Cleveland Clinic journal of medicine
  • 2002
TLDR
Patients at risk for renal adverse effects from NSAIDs can be prospectively identified, and the following patient populations are at higher risk for increases in blood pressure with concomitant use of an NSAID and an antihypertensive.
Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial
TLDR
The cardiovascular outcomes of a long-term follow-up of participants in the APPROVe study, a multicentre, randomised, placebo-controlled, double-blind trial, show use of rofecoxib is associated with increased rates of APTC events.
Managing the adverse effects of nonsteroidal anti-inflammatory drugs
TLDR
Since CV and GI risk are related to drug exposure, a reduction in the administered dose is recommended, but this strategy will not eliminate the hazard owing to a possible contribution of individual genetic background.
Persistence of NSAIDs at effect sites and rapid disappearance from side-effect compartments contributes to tolerability
  • K. Brune
  • Medicine
    Current medical research and opinion
  • 2007
TLDR
This specific pharmacokinetic behavior of some non-selective COX inhibitors, such as diclofenac and ibuprofen, may explain why these widely used, non-steroidal, anti-inflammatory compounds are relatively well suited for OTC use and why some are more appropriate for the therapy of certain pain conditions than others.
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population.
TLDR
The findings suggest that the variable risk of MI among NSAIDs that do not inhibit platelet COx-1 completely and persistently is largely related to their extent of COX-2 inhibition.
Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
TLDR
It is suggested that celecoxib in commonly used doses may not increase the risk, contradicts claims of a protective effect of naproxen, and raises serious questions about the safety of diclofenac, an older drug.
...
1
2
3
4
5
...